Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination – The REST trial study protocol
Taras Yevusiak, Alanna Weisman, Ravi Retnakaran, Sean Wharton, Daniel J Drucker, Caroline K Kramer · 2026
Read Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination – The REST trial study protocol by Taras Yevusiak, Alanna Weisman, Ravi Retnakaran, Sean Wharton, Daniel J Drucker, Caroline K Kramer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0354237.txt.
Description
Yevusiak and colleagues present a 2026 protocol for a trial called REST, about stopping the weight-loss drug semaglutide. The drug helps many people with obesity lose a large amount of weight and improves heart and metabolic health. Yet most people regain weight after stopping suddenly, and the health gains fade.
The trial will enroll people who have already lost at least a tenth of their body weight on the drug and whose weight has leveled off. Half will taper the dose slowly over sixteen weeks before stopping, and half will stop at once. The main measure is how much weight each group regains. Blood pressure across a full day and levels of a hunger hormone will also be tracked. The team expects that a slow taper will soften regain. Their design speaks to a common real-world problem: how to come off a drug many patients cannot take forever.
Catalog record
| CREATOR | Taras Yevusiak, Alanna Weisman, Ravi Retnakaran, Sean Wharton, Daniel J Drucker, Caroline K Kramer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18548 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |